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ABSTRACT
Objectives: Self versus proxy perspectives may produce different results
that are important for clinical decision-making and for assessing outcomes
in research studies. We examined differences in child versus parent report
of the child’s health-related quality of life (HRQOL) in a large prospective,
community-based study of newly diagnosed childhood epilepsy that
included children with epilepsy (case) and sibling controls.
Methods: HRQOL was assessed 8 to 9 years after initial diagnosis of
epilepsy in a subset of 143 case-control matched pairs using the Child
Health Questionnaire (CHQ), a generic HRQOL measure with child
(CHQ-CF87), and parent (CHQ-PF50) versions.
Results: There were no signiﬁcant differences between self-reported case
and sibling control HRQOL scores on 9 of 11 scales or 2 global items.
Nevertheless, parent ratings were signiﬁcantly better (higher HRQOL) for
sibling controls compared with epilepsy cases on 10 of 12 scales, global
behavior and general health items, and the physical and psychosocial
summary scores (P  0.05). Parent–child agreement was low for cases and
controls (kappa 0.27–0.33) for three single-item questions with the same
wording on parent and child versions. Parent ratings of the case’s HRQOL
were often signiﬁcantly associated with 5-year remission status and
current antiepileptic drug use, but the case’s self-reported HRQOL scores
were not. In contrast, current pharmacoresistance was often associated
with the child and parent ratings of the child’s HRQOL.
Conclusion: Children with epilepsy report HRQOL that is comparable to
that of sibling controls, while parents rate children with epilepsy as having
lower HRQOL than sibling controls. Measuring outcomes in studies of
this population should incorporate both perspectives.
Keywords: child and adolescent health, Child Health Questionnaire
(CHQ), epilepsy, health-related quality of life (HRQOL), outcomes
research, patient-reported outcomes, proxy.
Introduction
Epilepsy is one of the most common chronic neurological dis-
eases, affecting approximately 1% of the population [1].
Approximately one-half of epilepsy in the population ﬁrst occurs
during childhood. Children with epilepsy face many challenges
including but not limited to seizures; they often have learning,
cognitive and school difﬁculties, medication side effects, social
stigma, psychiatric comorbidity, and behavioral problems
[2–12]. Given these challenges, it is important to measure health-
related quality of life (HRQOL) in children with epilepsy.
HRQOL assessments in children, however, are complex;
although ideally elicited directly, proxy ratings are often used to
assess HRQOL in young children. Children, however, may have
different perspectives from that of their adult proxies. Identiﬁca-
tion of such potential differences is important for assessing out-
comes in research studies and for developing comprehensive
treatment programs for children and families with epilepsy.
Although a number of studies have evaluated HRQOL in
children with epilepsy, the source of report for HRQOL often
varies [13–18]. Modi et al. reported that children with a single
seizure, or with newly diagnosed untreated epilepsy, had signiﬁ-
cantly worse Pediatric Quality of Life Inventory (PedsQL) scores
compared with general population norms [17]. Sabaz et al.
reported that children with “symptomatic” epilepsy have worse
HRQOL than those with idiopathic epilepsy using the Child
Behavior Checklist (CBCL), the Child Health Questionnaire
(CHQ), the Quality of life in Childhood Epilepsy (QOLCE), and
the Child Seizure Proﬁle (CSP) [18]. In both of these studies,
HRQOL assessments were elicited by parent report only. Austin
et al. showed that youths with epilepsy had worse HRQOL than
youths with asthma; psychological, social, and school domains of
QOL were measured using ﬁve different instruments with child,
parent, or teacher report [13]. HRQOL for children with epi-
lepsy has also been assessed by child report directly; studies by
Devinsky et al. and Benavente-Aguilar et al. assessed self-report
of HRQOL in adolescents with epilepsy using the Quality of Life
in Epilepsy for Adolescents (QOLIE-AD 48) [15,16].
Few studies, however, have compared child and parent report
of HRQOL in children with epilepsy. Verhey et al. compared
parent and child report of HRQOL using the Health-Related
Quality of Life Measure for Children with Epilepsy (CHEQOL-
25), an epilepsy-targeted HRQOL measure [19]. Disagreement
was observed between child and parent reports for subjective
domains of HRQOL (secrecy and present worries); parent report
of HRQOL was lower, or worse, on all domains compared with
child report, with the exception of one domain, present worries.
Similarly, in a sample of children with ﬁrst-time seizures,
Hamiwka et al. found that compared with normative data,
parent report of HRQOL was lower on 6 out of 11 scales and 1
summary score on the CHQ, while children reported lower
HRQOL on only the change in health item [20]. Additionally, in
a sample of adolescents with epilepsy, Huberty et al. compared
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parent, child, and teacher behavioral ratings using the CBCL and
found that mother’s evaluations of their child’s behavioral prob-
lems were signiﬁcantly higher (or worse) than the youth’s evalu-
ations on 8 of 11 subscales [21]. Finally, although parent–child
agreement was high (r  0.5) in a sample of epilepsy patients
using the German version of the PedsQL, the mean responses of
child report of HRQOL were higher, or better, compared with
parent report on all scales, with the exception of a school func-
tioning domain [22]. These studies provide some preliminary
support for the hypothesis that children and parents report
HRQOL differently in children with epilepsy.
Understanding whether child versus parent perspectives
produce different results is important for clinical decision-
making and for planning research studies that focus on these
outcomes, particularly in children with epilepsy. Furthermore, as
children with epilepsy, or with other chronic diseases, become
adults, recognition of these potential differences may be impor-
tant for identifying those with special health needs requiring
transition support [23]. We examined parent versus child report
of HRQOL in a group of children with epilepsy and sibling
controls to parent report of HRQOL in these children at long-
term follow-up in a prospective, community-based cohort study
of newly diagnosed epilepsy.
Methods
Sample
The Connecticut Study of Epilepsy is a prospective, community-
based cohort study that recruited 613 children with newly diag-
nosed epilepsy between 1993 and 1997 with ongoing prospective
follow-up; details of methods, recruitment, and follow-up pro-
cedures have been published previously [24]. Initial enrollment
inclusion criteria included initial diagnosis of epilepsy by partici-
pating physicians (or diagnosis by a nonparticipating physician
with referral to a participating physician within 3 months of
diagnosis) during the recruitment period (January 1993–
December 1997) and ﬁrst of two or more unprovoked seizures
occurred between 1 month (28 days) through 15 years of age.
Eight to 9 years after initial enrollment (March 2002–
February 2006), 311 subjects from the original cohort and family
members of those subjects participated in a comprehensive reas-
sessment protocol; siblings without a neurological disability,
within 3 years of the patient’s age and less than 18 years of age
were also enrolled as controls [5]. The protocol included an
assessment of HRQOL reported by the child with epilepsy (case)
and a sibling control, and a parent’s assessment of both the case
and the sibling control’s HRQOL.
Institutional review board approval was obtained at all sites
(G07-07-094—University of California Los Angeles). Written
informed consent was obtained from the parent and written
assent from the child, at the time of initial enrollment and at the
8- to 9-year reassessment.
Data Collection
Clinical and demographic data of the cases and the parents were
obtained via a structured in-person interview (clinic or subject’s
home) with the parent or guardian interviewed by trained
research associates during initial enrollment [24]. This interview
included details of the child’s unprovoked or provoked seizures,
medical, and developmental history. All baseline medical records
were reviewed, and information including neurological examina-
tion, presence of mental retardation, neuroimaging ﬁndings, spe-
ciﬁc underlying etiology, history of prior provoked seizures,
presence of other medical conditions, and electroencephalogram
(EEG) ﬁndings were extracted and coded on an ongoing basis.
The families were called every 3 to 4 months by trained research
associates and asked whether their child had experienced any
interval seizures, and information regarding the dates, types of
seizures, and circumstances of any reported seizure, in addition
to any changes in antiepileptic medications were ascertained. The
patients and the families were asked to keep seizure logs. At the
8- to 9-year follow-up comprehensive reassessment, clinical and
demographic data of the cases, the parents, and the sibling con-
trols were obtained via a structured interview in-person (in a
clinic or the subject’s home) or via phone.
Measures
HRQOL was assessed using the CHQ, a self-administered,
generic HRQOL measure with child (CHQ-CF87) and parent
(CHQ-PF50) versions [25]. The CHQ-CF87 includes 87 items
used to create 11 scales (physical function, role/social
limitations—physical, role/social limitations—behavioral, role/
social limitations—emotional, mental health, self-esteem, behav-
ior, bodily pain/discomfort, general health perceptions, family
activities) and 2 global items (global behavior and global general
health). The CHQ-PF50 includes 50 items used to construct 12
scales (physical function, role/social limitations—physical, role/
social limitations—emotional/behavioral, mental health, self-
esteem, behavior, bodily pain/discomfort, general health
perceptions, family activities, parent impact on time, parent emo-
tional impact) and 2 global items (global behavior and global
general health); two summary scores (physical and a psychoso-
cial summary scores) can also be generated from the CHQ-PF50.
Raw scores for each scale are transformed to a 0 to 100 scale
with 0 representing worst health and 100 indicating best health.
Physical and psychosocial summary scores (CHQ-PF50 only) are
transformed to T-scores (mean = 50, SD = 10) calculated against
a general reference US population. The CHQ-CF87 and the
CHQ-PF50 contain similar but not identical items, making direct
score comparisons problematic except for three single-items that
have similar wording.
To compare construct validity across the case and the parent
versions, we examined associations of the case and the parent-
reported HRQOL measures with whether or not the child had
been seizure-free for at least 5 years at the time of the follow-up
reassessment, whether or not the child was currently taking
antiepileptic drugs (AEDs), whether the child’s epilepsy was asso-
ciated with a known structural or metabolic underlying cause, or
an electroclinical syndrome considered to be an epileptic
encephalopathy, designated here as “complicated epilepsy” [26],
and whether or not the child’s epilepsy was pharmacoresistant
and the child was not seizure-free for the last 5 years. Pharma-
coresistance was deﬁned as the failure of two different appropri-
ate AEDs to bring seizures under complete control when used as
prescribed and pushed to the maximum tolerated levels [27].
This deﬁnition is consistent with that proposed by the Task Force
of the International League Against Epilepsy Commission on
Therapeutic Strategies [28].
Analysis
Sociodemographic and clinical characteristics of the cases and
the controls and the parents were compared using bivariate sta-
tistics (matched t-tests, Wilcoxon rank-sum, chi-square). We esti-
mated internal consistency reliability (Cronbach’s alpha) for each
scale of the CHQ-CF87 and the CHQ-PF50 for the cases and the
controls.
Because direct comparisons between child and parent CHQ
versions were problematic, we compared self-reported HRQOL
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in the cases versus the sibling controls on the CHQ-CF87 and
then parent-reported HRQOL in the cases versus the sibling
controls on the CHQ-PF50. Only subjects for whom HRQOL
was evaluated for both the case and the sibling control, and for
whom HRQOL of the case and control were rated by the same
parent (n = 143) were included in this matched analysis. Mean
differences between the cases and the controls (child report and
parent report) were calculated. We compared the case versus the
control self-reported HRQOL means for the 11 scales and 2
global items of the CHQ-CF87 using matched or paired t-tests.
Similar analyses were performed to compare parent report of the
case versus the control HRQOL on the 12 scales, 2 global items,
and 2 summary scores of the CHQ-PF50. A sensitivity analysis
was performed excluding the 29 complicated cases, generally
associated with more severe neurological impairment. To
compare HRQOL responses to a reference healthy standard
population, parent report of the case and the control mean
HRQOL responses (CHQ-PF50) were compared with age-
adjusted and gender-adjusted norms using t-tests [25] (child-
reported norms from a representative US population of healthy
children are not available, thereby precluding a similar analysis
for the CHQ-CF87).
To assess the level of parent–child agreement, we calculated
weighted kappas between the case and the parent report of
HRQOL between parent and child on the single items that had
the same wording (bodily pain/discomfort, global general health,
and global behavior) [29].
We used a multitrait-multimethod matrix (MTMM) to assess
the construct validity for the case and the control HRQOL by
comparing child (CHQ-CF87) and parent (CHQ-PF50) reports
for the nine scales for which the child and parent versions have
common constructs or domains [30,31]. Correlations between
different methods (CHQ-CF87 vs. CHQ-PF50) should be higher
if they are assessing the same HRQOL domain compared with
when they are assessing different domains.
We assessed construct validity of the child and parent versions
of CHQ for epilepsy by evaluating child and parent report of
HRQOL for the cases with more severe disease compared with
those with less severe disease as reﬂected by their 5-year remis-
sion status, current AED use, having complicated epilepsy or not,
whether the epilepsy met the criteria for pharmacoresistant and
whether the child had not been seizure-free for the prior 5 years.
Only study participants whom the HRQOL was evaluated for
both the case and the parent were included in this analysis
(n = 279). We evaluated differences in mean HRQOL scores for
the cases that were seizure-free versus not seizure-free, taking
AEDs versus not taking AEDs, complicated versus not compli-
cated, and were currently pharmacoresistant versus not pharma-
coresistant using t-tests for both the child and parent report.
Analyses were performed using Stata (9.2; StataCorp LP,
College Station, TX), SAS (9.1; SAS Institute, Cary, NC), and the
MTMM.exe program (Santa Monica, CA) [31]. We used an a
priori p value of P  0.05 for statistical signiﬁcance.
Results
Sociodemographic and Clinical Characteristics
Sociodemographic and clinical characteristics for children,
sibling controls, and parents are shown in Table 1. The CHQwas
completed for both the case and the parent but with no sibling
control in 279 dyads. For the 143 cases, the CHQ was also
completed by sibling control, and the same parent rated HRQOL
in these 143 case-control pairs. There was no signiﬁcant differ-
ence in the parent–child testing dates between the cases and the
controls (P = 0.59).
Internal Consistency Reliability
Cronbach’s alphas were high, ranging from 0.75 to 0.90 for
CHQ-CF87 the subscales (Table 2) and from 0.74 to 0.97 for the
CHQ-PF50 subscales (Table 3). Because the CHQ-CF87 has
been recommended for ages 10 and over, we analyzed internal
consistency reliability for the subset of children aged 9 and under
(cases n = 18; controls n = 28). Cronbach’s alpha for all the
scales except one exceeded 0.80; Cronbach’s alpha was 0.69 for
one scale, general health perceptions.
Comparison of Child versus Parent Report of HRQOL
Using Matched Sibling Controls
There were no differences between the self-reported case and the
control HRQOL scores on 9 of the 11 scales and 2 global items
of the CHQ-CF87 (Table 2, Fig. 1a). The cases reported worse
HRQOL than the controls on the two scales: physical function
(P = 0.01) and role limitations—physical (P = 0.04). In contrast,
parent-report of HRQOL for the controls was signiﬁcantly better
than cases on 10 of the 12 scales, 2 global items, and both
summary scores of the CHQ-PF50 (all P  0.05) (Table 3,
Fig. 1b). Excluding the 29 complicated cases from our analyses,
the ﬁndings were similar except that the child and the sibling
control self-reports of HRQOL were now no different on all 11
CHQ-CF87 scales, and parent report of the case and the sibling
control HRQOL was still signiﬁcantly better on 10 of the 12
scales, both summary scores, and only 1 global item (global
general health).
Compared with age-adjusted norms, parent report of the case
HRQOL was signiﬁcantly lower for only 3 of the 12 scales
(P  0.01), although parent report of control HRQOL was sig-
niﬁcantly higher for 7 scales and both summary scores (P  0.01)
with the exception of one scale, family activities, which was
signiﬁcantly lower (P  0.05) (Table 3). Similar results were
found for parent report of the case and the control HRQOL
compared with gender-adjusted norms (results not shown).
Parent–Child Agreement
Parent–child agreement was low for the single items with the same
wording between the CHQ-CF87 and CHQ-PF50. Weighted
kappas ranged from 0.27 to 0.33 for the case-parent and 0.27 to
0.28 for the control-parent. MTMM analysis showed relatively
poor agreement between parent and child on common domains.
The average correlation between parent and child when reporting
on the same HRQOL domains was a little higher for the cases (r =
0.374) than the controls (r = 0.334), but the average correlation
was also higher when they were reporting on different domains
(r = 0.285 vs. r = 0.246). Evidence for construct validity was low;
only 82 out of the 288 (case) and 98 out of the 288 (control) t-tests
of the different pairs ofMTMMdiscriminant validity correlations
were signiﬁcant in the hypothesized direction.
Construct Validity of Child versus Parent Report
of HRQOL of Case (Child with Epilepsy) by
Disease Severity
In contrast to child self-report, where HRQOL was only infre-
quently associated with 5-year remission status, AED use, and
having complicated epilepsy, parent report of the case HRQOL
was often signiﬁcantly associated with CHQ-PF50 scales
(Table 4). For example, parent-reported HRQOL for the seizure-
free (n = 178) cases was signiﬁcantly better compared with the
nonseizure-free (n = 101) cases in 7 scales, 2 global items, and
both summary scores (P  0.03). In contrast, both parents’ and
children’s ratings of the child’s HRQOL were signiﬁcantly asso-
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ciated with pharmacoresistance status for about half the
HRQOL scales on the child and on the parent versions (Table 4).
Discussion
The measurement of HRQOL is more complex in children com-
pared with adults; the assessment of child HRQOL often relies
on a parent or guardian report. Children, however, may have
different perspectives from that of their adult proxies. We found
signiﬁcant differences in child self-report versus parent report of
HRQOL for children with epilepsy compared with sibling con-
trols. Overall, children with epilepsy report HRQOL that is
comparable with that of healthy sibling controls while parents
rated children with epilepsy as having lower or worse HRQOL
Table 1 Demographics and clinical characteristics for the children (cases and sibling controls) and the parents
Child demographics and clinical characteristics
Cases with parent
rating (n = 279)
Matched cases and sibling control pairs (n = 143)*
N (%)
Cases
N (%)
Controls
N (%)
Female 130 (46.6) 64 (44.8) 83 (58.0)
Age, in years, mean (SD) 13.0 (2.6) 12.6 (2.5) 12.0 (3.0)
Education
Preschool–5th grade 68 (24.9) 35 (25.0) 45 (31.7)
6th grade–8th grade 107 (39.2) 61 (43.6) 57 (40.1)
9th grade–12th grade 98 (35.9) 44 (31.4) 40 (28.2)
Seizure-free duration, yrs, median (IQR)† 6.7 (5.6) 6.7 (5.5) —
<1 year 48 (17.2) 27 (18.9) —
1 years (and <2 years) 14 (5.0) 5 (3.5) —
2 years (and <3 years) 14 (5.0) 9 (6.3) —
3 years (and <4 years) 13 (4.7) 2 (1.4) —
4 years (and <5 years) 12 (4.3) 6 (4.2) —
5 years 178 (63.8) 94 (65.7) —
Complicated epilepsy‡ 54 (19.4) 29 (20.3) —
Currently taking antiepileptic drugs (AEDs) 87 (31.2) 43 (30.1) —
1 AED 70 (25.1) 33 (23.1) —
2 AEDs 12 (4.3) 7 (4.9) —
3 AEDs 5 (1.8) 3 (2.1) —
Pharmacoresistance (present)§ 33 (11.8) 17 (11.9)
Parent demographics Parent with child
case rating (n = 279)
Parent of matched case and
sibling control pairs (n = 143)
Female 254 (91.0) 130 (90.9)
Age, yrs, mean (SD) 42.5 (5.5) 41.2 (5.3)
Race
Caucasian 224 (80.9) 115 (80.4)
African American 32 (11.6) 15 (10.5)
Other|| 21 (7.5) 13 (9.1)
College education or higher 120 (43.0) 61 (42.7)
Employed full or part time 217 (77.8) 110 (76.9)
Married 199 (71.6) 108 (76.0)
Biological Parent 267 (95.7) 142 (99.3)
*No differences in child demographics between case and sibling control, except for gender (P = 0.02).
†Time since last seizure (years) at the time of the 8- to 9-year follow-up reassessment.
‡Complicated deﬁned by history of remote symptomatic epilepsy or epileptic encephalopathy.
§Failure of two different appropriate antiepileptic drugs to bring seizures under complete control when used as prescribed and pushed to the maximum tolerated levels among those who were
not seizure-free for 5 years at the time of the 8- to 9-year follow-up reassessment.
||Includes Hispanic and Asian and other.
IQR, interquartile range.
Table 2 Descriptive statistics and reliability of child form Child Health Questionnaire (CHQ-CF87) scales
No. of
items
Cases (N = 143) Controls (N = 143)
Cronbach’s
alpha
Observed
Mean (SD)
Cronbach’s
alpha
Observed
Mean (SD)
Physical function* 9 0.85 92.3 (13.8) 0.83 95.2 (7.5)
Role/social limitations—physical* 3 0.86 93.9 (16.7) 0.79 97.1 (9.6)
Role/social limitations—behavioral 3 0.86 92.7 (16.1) 0.75 95.3 (11.4)
Role/Social limitations—emotional 3 0.80 91.0 (15.9) 0.70 93.6 (12.3)
Mental health 16 0.83 76.5 (14.2) 0.81 77.5 (14.2)
Self-esteem 14 0.90 81.8 (12.8) 0.89 82.4 (12.9)
Behavior 16 0.84 77.9 (13.6) 0.81 78.8 (12.7)
Bodily pain/discomfort 2 0.86 80.8 (19.7) 0.81 81.5 (19.7)
General health perceptions 12 0.75 73.0 (15.5) 0.75 73.0 (16.2)
Family activities 6 0.87 78.3 (22.1) 0.87 81.0 (21.4)
Family cohesion 1 — 74.4 (23.8) — 74.0 (23.3)
Global behavior 1 — 82.5 (17.6) — 81.9 (18.2)
Global general health 1 — 80.7 (19.0) — 80.9 (18.6)
*Signiﬁcant differences between cases and controls observed means P 0.05 (see Fig. 1a).
Sensitivity analysis excluding 29 complicated cases resulted in similar ﬁndings except that the child and the sibling self-reports of health-related quality of life (HRQOL) were no different on
all CHQ-CF-87 scales.
Note:All HRQOL scale scores range from 0 (worst) to 100 (best).
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than sibling controls broadly across multiple scales, with no
predominance of one domain. These results suggest children and
parents may not necessarily share similar views about the overall
impact of epilepsy.
There are several potential explanations for our ﬁndings.
First, the concerns of a child with epilepsy may differ from that
of a parent. For example, Arunkumar et al. reported that out of
26 identiﬁed concerns about living with epilepsy, children iden-
tiﬁed 5 domains that were not identiﬁed by parents (hatred of
seizures, dislike of hospital visits, dating, social embarrassment,
and headache) [32]. In this regard children and parents may draw
on different values and perspectives from which to evaluate
HRQOL. Children and parents, however, may not be aware of
these different perspectives [33]. Second, it is likely that parent
report of HRQOL for children with epilepsy is inﬂuenced by
parental anxiety that could lead to a lower or worse parent
report of HRQOL compared with the child report. Parental
anxiety may stem from the knowledge that children with epilepsy
face many challenges including, but not limited to seizures,
including behavior, psychiatric, learning, and school perfor-
mance problems [2–11], in addition to poor long-term outcomes
with respect to employment, educational attainment, socioeco-
nomic status, marital status, and QOL [34–37]. In fact, parents
are highly aware of the behavioral, emotional, and cognitive
difﬁculties faced by their children with epilepsy [38]. Parental
anxiety was found to be signiﬁcantly associated with decreased
QOL for children with epilepsy in a study by Williams et al. in
which parent ratings of QOL were measured using the Impact of
Childhood Illness Scale [39]. Lastly, having a chronic disease, or
disability, does not necessarily mean that a person is unsatisﬁed
with their life, despite what others may think—a term denoted
the disability paradox [40]. Such a paradox could explain our
ﬁndings that parent report of HRQOL was low compared with
child report. In this regard, parental perception of HRQOL may
be distorted because of having a “sick” child; such distortion
could not only lead to an underestimate of the HRQOL of the
child with epilepsy, but also, it may result in an overestimate of
the HRQOL of a “healthy” sibling—a phenomenon that could
explain our ﬁndings that parents viewed sibling controls as
having better HRQOL than general population controls.
Our ﬁndings are consistent with prior research, which has
suggested that parents of children with health conditions tend to
underestimate the child’s HRQOL [41]. In fact, parent report of
lower or worse HRQOL compared with child report has been
observed in a number of different disease states including cancer,
asthma, diabetes, inﬂammatory bowel disease, and attention-
deﬁcit disorder [12,22,42–45]. Few studies, however, have evalu-
ated parent child differences in the report of HRQOL in children
with epilepsy [19,20,22]. Verhey et al. found that parents rated
children’s HRQOL lower compared with the child’s report as
measured by an epilepsy-speciﬁc measure, the CHEQOL-25 [19].
Only a small proportion of children in this sample, however, was
seizure-free (11.5% seizure-free for 12 months). In contrast, our
sample uniquely identiﬁes these parent–child differences in a
sample of children with predominantly well-controlled epilepsy
(>60% were seizure-free for 5 years). Furthermore, although
Hamiwka et al. reported child–parent differences in a sample of
ﬁrst-time seizure patients, this study was limited by the fact that
comparisons were made with different parent and child norma-
tive samples; the CHQ-CF87 norms were based on an Australian
normative sample, while the CHQ-PF50 norms were based on a
US normative sample [20]. Additionally, Felder-Puig et al. found
that parent report of HRQOL was lower compared with the
child report of HRQOL using a German version of the generic
PedsQL [22]. Nevertheless, the epilepsy sample in this study was
small (n = 41) and no clinical information was provided regard-
ing epilepsy disease severity (seizure frequency or remission
status). Finally, in a sample of adolescents with epilepsy, Huberty
et al. found that adults (parents and teachers) tended to agree
with each other than with youths, with youths reporting fewer
problems than adults [21]. Although analogous to our ﬁndings,
the Hubert study focused on analyzing different informant per-
spectives of behavior, while we analyzed differences in perspec-
tives on HRQOL.
There are several limitations to our study. First, because the
CHQ is a generic instrument, it may not be sensitive to the
nuances of epilepsy. Although published data are available evalu-
ating the use of the CHQ-PF50 in a sample of children who
underwent resective epilepsy surgery, no such data are available
for the CHQ-CF87 [25]. As such, the differences that we found
Table 3 Descriptive statistics and reliability of parent form Child Health Questionnaire (CHQ-PF50) scales
# of
items
Case (N = 143) Control (N = 143)
Cronbach’s
alpha
Observed
Mean (SD)
Age adjusted
norms
Cronbach’s
alpha
Observed
Mean (SD)
Age adjusted
norms
Physical function* 6 0.93 94.8 (13.6) 96.1 0.89 98.4 (6.0) 96.0****
Role/social limitations—physical* 2 0.97 93.2 (18.7) 93.3 0.83 98.3 (7.3) 93.6****
Role/social limitations—emotional/behavioral* 3 0.97 84.5 (29.1) 91.9*** 0.88 95.5 (14.8) 92.1***
Mental health* 5 0.81 77.8 (16.2) 77.7 0.68 82.1 (11.7) 78.2****
Self-esteem 6 0.85 78.1 (19.4) 77.9 0.87 80.4 (18.7) 78.8
Behavior* 5 0.84 74.4 (18.9) 75.6 0.83 79.4 (16.4) 75.5***
Bodily pain/ discomfort 2 0.91 81.0 (19.8) 81.7 0.93 83.4 (18.9) 81.6
General health perceptions* 5 0.70 71.9 (17.1) 72.8 0.60 79.8 (14.5) 72.9****
Family activities* 6 0.94 81.7 (21.8) 89.7**** 0.89 87.2 (15.9) 89.9**
Family cohesion* 1 — 70.4 (22.7) 71.2 — 72.7 (20.7) 71.6
Global behavior* 1 — 76.4 (25.0) — — 80.8 (20.6) —
Global general health* 1 — 85.0 (17.7) — — 90.1 (12.2) —
Parent impact on time* 3 0.80 86.5 (22.7) 87.4 0.73 95.0 (12.8) 87.7****
Parent emotional impact* 3 0.74 70.5 (26.2) 80.0**** 0.60 82.6 (19.1) 80.3
Summary scores (T-scores)
Physical summary score* — — 52.2 (8.4) 53.1 — 55.4 (5.3) 53.1****
Psychosocial summary score* — — 49.0 (12.0) 50.7 — 53.3 (7.9) 51.0***
*Signiﬁcant differences between cases and controls observed means P 0.05 (see Fig. 1b).
Signiﬁcant differences between cases or controls observed means and age-adjusted norms, **P 0.05; ***P 0.01; ****P 0.0001.
Note: All HRQOL scale scores range from 0 (worst) to 100 (best), except for the physical and psychosocial summary scores, which are T-scores (mean = 50, SD = 10) calculated against a
reference population (Landgraf, 1996).
Sensitivity analysis excluding 29 complicated cases resulted in similar ﬁndings except that global behavior no longer signiﬁcantly different.
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may reﬂect our ﬁnding of better construct validity for epilepsy
disease severity in the CHQ-PF50 compared with the CHQ-
CF87, perhaps suggesting that parent reports are more valid than
child self-reports in this population. Second, the CHQ-CF87 and
the CHQ-PF50 have varied item wording and scale length,
making direct comparisons of agreement across the measures
problematic; we did, however, ﬁnd low parent–child agreement
on the three items with the same wording between parent and
child versions [41]. Furthermore, our comparison of child and
parent report of HRQOL with that of a sibling control, however,
allows for indirect comparisons between the child and parent
versions. Third, although the CHQ-CF87 is primarily intended
for administration in children ages 10 to 18 years, we included
children under age 10 (18% cases and 28% sibling controls in
the matched case-control sample). Internal consistency reliability
for the subsample, however, was high (Cronbach’s alpha 0.80
for all but one scale). Fourth, although we noted statistically
signiﬁcant differences on multiple domains of HRQOL in the
parent report of the case compared with the sibling
control—only differences in seven of the scales (role/social
limitations—physical, role/social limitations—emotion/behavior,
behavior, general health perceptions, family activities, parent
impact on time, parent emotional impact) and the one global
general health item may represent clinically meaningful differ-
ences (>ﬁve points) [25]. Furthermore, we did not correct for
multiple comparisons, although we used an a priori P-value of
P  0.05 for statistical signiﬁcance; nevertheless, we note that
the outcomes (dependent variable) are correlated, and a strict
adjustment would be too conservative. Lastly, the generalizability
of our ﬁndings may be limited not only because we were only
able to compare the CHQ-PF50 with normative data because
there is no US-based normative data for the CHQ-CF87, but also
because our sample population was relatively homogeneous; the
subjects were recruited from only one US state (Connecticut),
Figure 1 The sibling control health-related
quality of life (HRQOL) scores minus the case
HRQOL scores for (a) child self-report (CHQ-
CF87), and (b) parent report (CHQ-PF50). The (a)
cases reported worse HRQOL than the controls
on only 2 scales, while (b) parent report of
HRQOL for the controls was signiﬁcantly better
than the cases on 10 or 12 scales, 2 global items,
and both summary scores of the CHQ-PF50. Sen-
sitivity analysis excluding 29 complicated cases
resulted in similar ﬁndings except that child and
sibling self-reports of HRQOL were no different
on all CHQ-CF87 scales while parent report of
case and sibling control HRQOL was still signiﬁ-
cantly better on 10 of the 12 scales, both summary
scores, and only 1 global item (global general
health). CHQ, Child Health Questionnaire.
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and were predominantly Caucasian (>80%), and highly educated
(43% of the parents had college education or higher). The pre-
dominance of subjects with relatively high socioeconomic status
in our sample, however, may explain our ﬁnding that parent
report of HRQOL for the sibling control was higher compared
with normative data.
This study uniquely showed differences in parent and child
report of HRQOL in a prospective, community-based sample of
children with predominantly well-controlled epilepsy compared
with sibling controls. Because parent ratings are often used to
assess HRQOL in children, it is important to understand that
children and parents may have different perspectives, both of
which need to be taken into account when assessing HRQOL.
Patient-reported outcomes, including HRQOL, are increasingly
being recognized as an important outcome measure in research
studies, particularly in clinical antiepileptic medication trials and
prospective studies evaluating surgical outcomes. Furthermore,
the evaluation of HRQOL is essential for developing disease
management programs for children and families with epilepsy
that not only provide comprehensive treatment and education,
but also help facilitate dialog between parents and children given
the different perspectives that each may have. Understanding the
potential different, yet valuable, perspectives provided by parents
and children is integral to these evaluations and also for devel-
oping appropriate support services targeted for children as they
transition into adulthood. As such, future studies are needed to
further validate our ﬁndings and to elucidate the factors that may
drive these potential differences.
Source of ﬁnancial support: Supported by grant from National Institutes
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Minority Elderly (RCMAR/CHIME), NIH/NIA Grant Award Number
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